

Kazuhito Kawata

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4783004/publications.pdf>

Version: 2024-02-01

47
papers

824
citations

471371

17
h-index

552653

26
g-index

52
all docs

52
docs citations

52
times ranked

847
citing authors

#	ARTICLE	IF	CITATIONS
1	Bezafibrate Improves GLOBE and UKâ€PBC Scores and Longâ€Term Outcomes in Patients With Primary Biliary Cholangitis. <i>Hepatology</i> , 2019, 70, 2035-2046.	3.6	83
2	Neutrophilâ€toâ€lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. <i>Liver International</i> , 2020, 40, 968-976.	1.9	51
3	Identification of Potential Cytokine Pathways for Therapeutic Intervention in Murine Primary Biliary Cirrhosis. <i>PLoS ONE</i> , 2013, 8, e74225.	1.1	49
4	Enhanced Hepatic Nrf2 Activation After Ursodeoxycholic Acid Treatment in Patients with Primary Biliary Cirrhosis. <i>Antioxidants and Redox Signaling</i> , 2010, 13, 259-268.	2.5	48
5	Lenvatinib versus sorafenib in firstâ€line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. <i>Liver International</i> , 2021, 41, 1389-1397.	1.9	45
6	Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Childâ€Pugh class A or B liver function in realâ€world clinical practice. <i>Hepatology Research</i> , 2022, 52, 773-783.	1.8	34
7	Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. <i>Scientific Reports</i> , 2021, 11, 16663.	1.6	30
8	Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 370-379.	2.4	30
9	The Immunophysiology and Apoptosis of Biliary Epithelial Cells: Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 43, 230-241.	2.9	28
10	Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1812-1819.	1.4	28
11	Neutrophilâ€lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 698-706.	0.8	27
12	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLCâ€B stage patients classified as beyond up to seven criteria â€“ Multicenter analysis. <i>Hepatology Research</i> , 2022, 52, 308-316.	1.8	25
13	Does firstâ€line treatment have prognostic impact for unresectable <sc>HCC</sc>?â€Atezolizumab plus bevacizumab versus lenvatinib. <i>Cancer Medicine</i> , 2023, 12, 325-334.	1.3	25
14	Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2020, 98, 295-302.	0.9	24
15	Critical role of CREBHâ€mediated induction of transforming growth factor Î²2 by hepatitis C virus infection in fibrogenic responses in hepatic stellate cells. <i>Hepatology</i> , 2017, 66, 1430-1443.	3.6	23
16	Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b. <i>Gut and Liver</i> , 2018, 12, 201-207.	1.4	22
17	Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma. <i>Gastroenterology Report</i> , 2021, 9, 133-138.	0.6	21
18	Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis. <i>Cancer Medicine</i> , 2022, 11, 3796-3808.	1.3	21

#	ARTICLE	IF	CITATIONS
19	Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. <i>Liver International</i> , 2021, 41, 2997-3008.	1.9	18
20	Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. <i>Hepatology Research</i> , 2022, 52, 462-470.	1.8	18
21	Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study. <i>Infectious Diseases and Therapy</i> , 2020, 9, 851-866.	1.8	16
22	Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. <i>Hepatology Research</i> , 2021, 51, 880-889.	1.8	15
23	A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis. <i>Liver International</i> , 2020, 40, 1926-1933.	1.9	14
24	Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib. <i>Scientific Reports</i> , 2021, 11, 14474.	1.6	13
25	Clinical characteristics and risk factors for stent-stone complex formation following biliary plastic stent placement in patients with common bile duct stones. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2018, 25, 448-454.	1.4	12
26	What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?. <i>Liver Cancer</i> , 2021, 10, 115-125.	4.2	12
27	Ursodeoxycholic acid impairs liver-infiltrating T cell chemotaxis through IFN γ and CX3CL1 production in primary biliary cholangitis. <i>European Journal of Immunology</i> , 2021, 51, 1519-1530.	1.6	10
28	Platelet-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 32, 261-268.	0.8	9
29	Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4939.	1.8	8
30	Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case-control study. <i>Journal of Gastroenterology</i> , 2022, 57, 19-29.	2.3	8
31	The ursodeoxycholic acid response score predicts pathological features in primary biliary cholangitis. <i>Hepatology Research</i> , 2021, 51, 80-89.	1.8	7
32	Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis. <i>Hepatology Research</i> , 2022, 52, 235-246.	1.8	7
33	A case of a primary hepatic so-called adenocarcinoma with heterotopic ossification: possibly of biliary adenofibroma origin. <i>Human Pathology</i> , 2018, 73, 108-113.	1.1	5
34	Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis. <i>Oncology</i> , 2021, 99, 518-527.	0.9	5
35	Dilated main pancreatic duct can be a negative predictor of pancreatitis related to biliary SEMS insertion across the papilla. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 865-869.	0.6	4
36	C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. <i>Scientific Reports</i> , 2022, 12, 8421.	1.6	4

#	ARTICLE	IF	CITATIONS
37	Improved Serum Alpha-Fetoprotein Levels after Iron Reduction Therapy in HCV Patients. <i>ISRN Hepatology</i> , 2014, 2014, 1-7.	0.9	3
38	Successful Interferon Therapy Reverses Enhanced Hepatic Progenitor Cell Activation in Patients with Chronic Hepatitis C. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 956-962.	0.5	3
39	Giant Hepatomegaly with Spleno-testicular Enlargement in a Patient with Apolipoprotein A-I Amyloidosis: An Uncommon Type of Amyloidosis in Japan. <i>Internal Medicine</i> , 2021, 60, 575-581.	0.3	3
40	Mac-2-binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C. <i>Hepatology Communications</i> , 2022, 6, 1855-1869.	2.0	3
41	Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 857-864.	0.8	3
42	Hemorrhagic radiation gastritis successfully treated with repeated intra-arterial steroid infusions. <i>Clinical Journal of Gastroenterology</i> , 2011, 4, 34-38.	0.4	2
43	Emergence of anti-mitochondrial M2 antibody in patient with angioimmunoblastic T-cell lymphoma. <i>Clinical Journal of Gastroenterology</i> , 2018, 11, 302-308.	0.4	2
44	Chorea induced by simeprevir and PEG-IFN and rivabirin therapy for chronic hepatitis C. <i>Acta Hepatologica Japonica</i> , 2015, 56, 103-108.	0.0	1
45	Mesenchymal hamartoma of the liver: Report of a case and review of the literature. <i>Acta Hepatologica Japonica</i> , 2014, 55, 756-763.	0.0	0
46	Spontaneous clearance of serum hepatitis C virus RNA in an untreated patient with decompensated cirrhosis. <i>Acta Hepatologica Japonica</i> , 2021, 62, 555-560.	0.0	0
47	Factors Related to the Beneficial Effects of Tolvaptan Treatment for Hepatic Ascites. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2016, 47, 17-20.	0.1	0